Trump DOJ Moves Forward on Marijuana Reclassification Despite Republican Opposition

President Donald Trump's Department of Justice has taken significant action to reclassify marijuana under federal law, building on Trump's December 2025 executive order that promised expanded medical research opportunities. Acting Attorney General Todd Blanche signed the reclassification order on Thursday, marking a pivotal moment in federal drug policy.

Building on Campaign Promises

The DOJ's move represents the fulfillment of a key Trump administration promise to modernize America's approach to medical marijuana. Blanche emphasized that the reclassification delivers on "President Trump's promise" to expand medical options for Americans who need them most.

"This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information," Blanche stated in his official announcement.

From Schedule I to Schedule III

The Justice Department announced updates to expedite removing marijuana from Schedule I and placing it in Schedule III under the Controlled Substances Act. This represents a dramatic shift in federal classification, moving cannabis from the same category as heroin to a group that includes ketamine, anabolic steroids, and prescription codeine medications.

Interestingly, this builds upon groundwork laid during the Biden administration, which had initiated the rescheduling process but never finalized the rule. The Trump administration has now taken decisive action to complete what the previous administration started.

State-Licensed Medical Focus

The order specifically targets state-licensed medical marijuana, providing regulatory clarity that has been absent for years. A White House official told the Daily Mail that the administration continues to "expeditiously implement President Trump's December executive order to increase medical marijuana research to close the gap between current medical marijuana use and medical knowledge."

DEA Administrator Terry Cole emphasized the enforcement priorities remain unchanged: "Our men and women in law enforcement remain committed to fighting drug cartels, the fentanyl epidemic, and protecting American lives."

Strict Limitations Remain

The DOJ made clear that significant restrictions continue to apply. The order explicitly states that "any form of marijuana other than in an FDA-approved drug product or marijuana subject to a state medical marijuana license remains a schedule I controlled substance."

This means recreational marijuana and unlicensed cannabis operations will continue facing the full weight of federal enforcement, with users and distributors remaining "subject to the regulatory controls, and administrative, civil, and criminal sanctions."

State-Level Momentum

The federal action comes as states have increasingly embraced marijuana legalization. Currently, 24 states and Washington, DC, allow recreational use, while 38 states permit medicinal marijuana. This patchwork of state laws has created ongoing tension with federal prohibition that the Trump administration now seeks to address systematically.

Republican Resistance Emerges

Not all Republicans support the administration's approach. Rep. Andy Harris (R-MD), who chairs the Freedom Caucus and practices medicine, voiced strong opposition to the reclassification.

"We don't need rescheduling to do medical research on marijuana–all we are doing is exposing more of our youth to an addictive drug," Harris argued, highlighting concerns about potential youth access and addiction risks.

This internal Republican opposition suggests the Trump administration may face pushback from conservative allies who prefer maintaining stricter federal prohibition.

Looking Forward

The DOJ's action represents a significant policy evolution for the Trump administration, which took a harder line on marijuana enforcement during Trump's first term. The focus on medical research and state-licensed programs suggests a more targeted approach that aims to balance law enforcement priorities with medical access needs.

As the rulemaking process moves forward, the administration will likely face continued scrutiny from both supporters pushing for broader legalization and conservative critics concerned about potential social consequences. The ultimate success of this policy shift will depend on implementation details and whether it can maintain bipartisan support while addressing legitimate medical research needs.